Request Demo
Last update 14 Mar 2026
Human Serum Albumin(Mitsubishi Tanabe Pharma Corp.)
Last update 14 Mar 2026
Overview
Basic Info
Drug Type HSA fusion protein |
Synonyms Albrec, Medway, Recombinant human serum albumin + [5] |
Target |
Action agonists |
Mechanism albumin agonists(Serum albumin agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseWithdrawn |
First Approval Date Japan (19 Oct 2007), |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 160295289
Related
2
Clinical Trials associated with Human Serum Albumin(Mitsubishi Tanabe Pharma Corp.)NCT01843894
A Phase 1/2, First-in-Human, Double-Masked, Placebo-Controlled, Dose-Escalation Study Evaluating the Safety, Tolerability, and Efficacy of RU-101 Ophthalmic Solution in Patients With Severe Dry Eye
NCT01919710
Phase 1 Study of rHSA/GCSF in Neutropenia After Chemotherapy of Cancer Patients
100 Clinical Results associated with Human Serum Albumin(Mitsubishi Tanabe Pharma Corp.)
Login to view more data
100 Translational Medicine associated with Human Serum Albumin(Mitsubishi Tanabe Pharma Corp.)
Login to view more data
100 Patents (Medical) associated with Human Serum Albumin(Mitsubishi Tanabe Pharma Corp.)
Login to view more data
117
Literatures (Medical) associated with Human Serum Albumin(Mitsubishi Tanabe Pharma Corp.)01 Feb 2026Hepatology International
Response to letter to the editor “Methodological considerations for recombinant human serum albumin clinical translation”
Letter
Author: Wang, Xinrui ; Niu, Junqi
01 Feb 2026Hepatology International
Methodological considerations for recombinant human serum albumin clinical translation
Letter
Author: Ruan, Bing ; Pan, Linye
01 Feb 2026Hepatology International
Recombinant human serum albumin: a true therapeutic substitute or merely a serum level elevator?
Letter
Author: Zhu, Xudong ; Liu, Yefu ; Dai, Junze
100 Deals associated with Human Serum Albumin(Mitsubishi Tanabe Pharma Corp.)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hypoalbuminemia | Japan | 19 Oct 2007 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hemophilia | NDA/BLA | Japan | 01 Oct 2007 | |
| Dry Eye Syndromes | Phase 2 | United States | 01 Apr 2013 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free